Stay updated on BBI503 Combo with Anti-Cancer Agents Clinical Trial

Sign up to get notified when there's something new on the BBI503 Combo with Anti-Cancer Agents Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BBI503 Combo with Anti-Cancer Agents Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The clinical trial record for the BBI503 combination study is displayed, including its interventions, eligibility criteria, study locations, and outcome measures. The study is marked completed and no longer recruiting.
    Difference
    66%
    Check dated 2026-11-08T02:29:18.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The site footer now identifies the platform as revision v3.8.0 instead of v3.7.2. The study page continues to display a 403 Forbidden error rather than study details.
    Difference
    0.2%
    Check dated 2026-10-31T22:26:40.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A notice was added at the top of the page announcing NIH website updates and a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T22:25:12.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-17T22:33:25.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1, while the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-10T22:19:56.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Revision: v3.7.0 was added to the page. A broad set of drug names, chemical classes, and related MeSH terms were removed from the study's indexed terms (examples include Sunitinib, Paclitaxel, pembrolizumab, Nivolumab, Doxorubicin, and Capecitabine).
    Difference
    21%
    Check dated 2026-09-19T20:46:22.000Z thumbnail image

Stay in the know with updates to BBI503 Combo with Anti-Cancer Agents Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BBI503 Combo with Anti-Cancer Agents Clinical Trial page.